[Experiences with an organ-saving and adjuvant-therapy concept in stage 1 XXXX after 6 years of use within the scope of a controlled clinical study].

@entity1 @entity440 @entity0 @entity5 @entity262 @entity1431 @entity3
Between 1979 and 1983 56 @entity1 with @entity0 underwent tumorectomy plus lymphadenectomy, postoperative irradiation and adjuvant antioestrogen therapy in cases of hormone receptor positive @entity5 . All @entity1 with hormone receptor negative @entity5 received 6 cycles of combined CMF chemotherapy instead of antioestrogen therapy. It was possible to complete optimal dosage of CMF or @entity440 in more than 85% of our @entity1 . @entity1431 occurred in only 3 @entity1 given chemotherapy, whilst intolerable gastrointestinal side effects occurred in 4 patients given antioestrogen therapy. No interference was detected between irradiation and chemo- or hormone therapy and no serious local complications with functional impairment were registered. 23% of the @entity1 had positive axillary nodes at the time of operation. The preoperative staging proved incorrect in 16% of cases, the @entity5 size exceeding 2 cm. After a mean follow-up period of 36 months the local recurrence rate was 3.6% and distant @entity3 appeared in 9% of @entity1 , whereby there was a significant dependence on lymph node status. No @entity1 died of @entity5 during the observation period. In view of the hypothesis that @entity0 is a @entity262 more attention should be paid to local cosmetic results and to systemic adjuvant therapy.
